— Why it moved
Why PRFX Stock Gapped and Faded Today — May 29, 2026
A preclinical painkiller study gapped this 764K-share float from $1.37 to over $6 premarket — by the close it sat 38% below the alert.
## What moved it The evening before, PRF Technologies (formerly PainReform) reported that its PRF-110 post-surgical painkiller matched an approved benchmark with 72 hours of analgesic activity in a head-to-head preclinical study. Preclinical, in a company that had printed an all-time low of $1.28 eight days earlier.
## The mechanics 764K shares in the float on a ~$2.6M cap. It takes very little buying to send that from $1.37 to $6 before most people are awake, and very little selling to unwind it. Day volume ran about 75 times the float.
## Numbers - Cap: ~$2.6M / float: 764K - Day volume: ~57M vs 0.8M avg - Prev close: $1.37 → alert at $4.84, already +253% - 52w range: $1.28–$17.95
## Where it ended up Stock Pulse flagged it premarket at 7:08 AM, $4.84 — the $6.30 premarket high had already printed earlier. It managed $5.39 four minutes into the regular session, chopped sideways for hours, then the floor gave way around 2:30 PM. It closed at $2.9999, 38% below the alert and 44% off the peak.
## Reality check - The fade is the whole story here. Best case +11%, actual close −38%. - Preclinical data from a rebranded shell that pivoted from pain drugs into "healthcare and AI-driven energy." - This already happened. Nothing here is a reason to touch it now.